DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Barclays Initiates Coverage On Epizyme with Overweight Rating, Announces $33 Price Target

Barclays analyst Peter Lawson initiates coverage on Epizyme (NASDAQ:EPZM) with a Overweight rating and a $33 price target.

Benzinga · 03/04/2020 10:38

Barclays analyst Peter Lawson initiates coverage on Epizyme (NASDAQ:EPZM) with a Overweight rating and a $33 price target.